Breaking News From Pharma & Bio Ingredients
Lonza Invests in Vitamin B3 Plant
Posted on 2008-04-03 07:27:00
Lonza will expand manufacturing capacity for nicotinates in order to meet growing market demand. The new facility will provide an additional 15,000 metric tons of product per year, representing an increase of more than 40% over current capacity. The first phase of the expansion is expected to be completed in 2011.
A location has not been finalized. Current manufacturing plants for nicotinates are located in Visp, Switzerland; Guangzhou, China and Nansha, China.
"The new capcity in nicotinates is important for us to be able to meet the long-term demands of our customers," said Lukas Utiger, executive vice president and head of Lonza Life Science Ingredinets. "In addition, we are excited about the continued implementation of technologies and new processes that will secure our long-term cost leadership in this market."
Subscribe via RSS
